Eli Lilly is testing a drug from the same family as its blockbuster obesity and diabetes medicines — but aimed at the brain rather than the waistline. The candidate, brenipatide, showed enough early promise that Lilly is advancing it directly into Phase III trials for depression and alcohol use disorder.

A familiar class, retuned

Brenipatide is a dual GIP/GLP-1 receptor agonist — the same mechanism as Lilly’s hugely successful tirzepatide (Mounjaro/Zepbound). But where tirzepatide is optimized for metabolism, brenipatide is designed to engage central nervous system and inflammatory pathways tied to reward, addiction and psychiatric symptoms. It reflects a fast-growing scientific interest in the idea that GLP-1-class drugs do more than curb appetite — they may dial down the brain’s reward and craving circuitry more broadly.

Why GLP-1 drugs are being eyed for the mind

Anecdotes and early studies have hinted that people on GLP-1 medicines sometimes drink less alcohol, smoke less, and report mood changes. The biology is plausible: GLP-1 signaling reaches brain regions involved in reward and motivation, and these drugs also have anti-inflammatory effects, and inflammation is increasingly implicated in depression and addiction. Brenipatide is an attempt to deliberately engineer those brain effects rather than treat them as a side benefit.

The early data

Phase I results supported once-weekly dosing, with a long half-life of 9–12.5 days. It was well tolerated across body sizes; only about 2.2% of participants discontinued due to side effects, with no deaths or serious adverse events, and the usual GLP-1-class gastrointestinal side effects appearing at similar rates in drug and placebo groups (about 25% each). “Having that longer half-life is some of the reason why we think there’s a distinct profile for brenipatide,” said Lilly’s Robert Nicholson.

An unusually broad program

Lilly is casting a wide net. Beyond the Phase III programs in major depressive disorder (which affects ~21 million U.S. adults a year) and alcohol use disorder (~27.9 million Americans), it has Phase II trials in tobacco and opioid use disorders, bipolar disorder and schizophrenia, plus immunology studies in asthma, IBS and COPD. Notably, Lilly skipped Phase II for depression and alcohol use disorder, going straight to pivotal trials — a sign of confidence and of the enormous patient populations at stake. Also telling: the alcohol trials will measure overall change in drinking patterns, not just total abstinence, reflecting a more modern, harm-reduction-friendly view of treatment success.

Why it matters — and the caveats

If it works, brenipatide could bring a new mechanism to psychiatric and addiction medicine, fields that have seen few genuinely novel drug classes in years. But the caution is real: this is largely a Phase I-to-III leap, and the brain is where many promising drugs fail. Efficacy in depression and addiction is notoriously hard to prove, placebo responses are high, and skipping Phase II raises the stakes. Broad ambition is not the same as proven benefit — the pivotal trials will decide. Business and clinical news, not investment or medical advice.